The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.

The estrogen receptor-positive (ER+) subtype accounts for 70% of all mammary carcinoma (MC) cases. ER+ MC patients display a prolonged clinical dormancy state, with a 70% recurrence 5-20 years after ...

Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.